Gene Signal Announces Publication of Phase I Data Highlighting Safety of GS-101 for Diseases of the Eye
GS-101 Being Evaluated in Phase III to Prevent Corneal Graft Rejection
12-Aug-2009 -
Gene Signal, a company focused on developing innovative drugs to manage angiogenesis based conditions, announced publication of data from a phase I study demonstrating that the antisense oligonucleotide GS-101 (eye drops) is safe, with no signs of intolerability following administration to ...
angiogenesis
bioavailability
diseases
+5